ArticleCureus2026
Role of Systemic Immune-Inflammatory Index and WBC Differential in Predicting the Severity of Acute Pulmonary Embolism: A Single-Center Observational Study at King Fahad Specialist Hospital, Buraydah, Saudi Arabia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Early identification of high-risk pulmonary embolism (PE) is crucial for improving patient outcomes. The systemic immune‑inflammatory index (SII) has emerged as a potential biomarker of thromboinflammatory activity. This study aimed to assess the roles of SII and white blood cell (WBC) differentiation in predicting the severity of acute PE (APE). Methods This was a retrospective study of patients with APE admitted to King Fahad Specialist Hospital in Saudi Arabia from 2022 to 2025. Data included demographics, chronic diseases, and clinical features. Furthermore, vital signs, oxygen saturation, complete blood count with differential, echocardiography, and computed tomography angiography results at admission, and mortality rate were collected. All patients were classified according to severity using the Pulmonary Embolism Severity Index (PESI) score and PE risk stratification as massive, submassive, or non-massive. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, New York, United States). Results Among the 166 patients with APE (mean age: 57.1 years) included in this study, 93 patients (56%) were female, and hypertension and diabetes were the most common comorbidities, with 73 (44%) and 61 (36.7%) having them, respectively. Levels of inflammatory markers (WBC and neutrophils) and cardiac biomarkers (troponin) are markedly elevated in patients with massive PE. Receiver operating characteristic analysis showed that neutrophil count (area under the curve: 0.766), WBC (0.736), and SII (0.656) had good predictive accuracy for massive PE, but platelet count was not a useful predictor (p = 0.089). PESI scores demonstrated a strong association with PE severity, increasing stepwise from non‑massive to massive PE (78.6 ± 37.4 vs. 84.2 ± 32.9 vs. 136.5 ± 54.9; p < 0.001). Conclusion Elevated SII, neutrophil count, and WBC count were significantly associated with massive PE and adverse outcomes. These markers offer value for early risk stratification and may enhance clinical decision-making in the management of APE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.